Thomas Vanassche - Concepedia

Author

Thomas Vanassche

Also Known As

Alicia Vilaseca, C. Ay, Caroline Martens, Christophe Vandenbriele, Hanna M. Ollila, I Pabinger, I. Pabinger, Kathleen Freson, L. Liesenborghs, Luca Valerio

328

Publications

8.4K

Citations

H-Index

Concepts

All Affiliations

KU Leuven McMaster University Universidad Católica de Murcia Population Health Research Institute Hospital Universitari Germans Trias i Pujol

About

Thomas Vanassche is an author at KU Leuven specializing in medicine, thrombosis, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	37	2.6K
2	Public Health	11	12	645
3	Health Sciences	4	4	160
4	Engineering	1	1	13
5	Allergy	1	1	42

Thomas Vanassche

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation Jan Steffel, Rónán Collins, Matthias Antz, EP Europace	2021	1K
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial Sonia S. Anand, Jackie Bosch, John W. Eikelboom, The Lancet ThrombosisCardiovascular DiseaseStrokeMedicinePlacebo-controlled Trial	2017	855
Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant James D. Douketis, Alex C. Spyropoulos, Joanne Duncan, JAMA Internal Medicine	2019	474
Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES Thomas Vanassche, Mandy N. Lauw, John W. Eikelboom, European Heart Journal	2014	311
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly, The Lancet ThrombosisDose-finding Phase 2Cardiovascular DiseasePharmacologyCardiovascular Pharmacology	2022	296
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial Markus P. Schlaich, M Bellet, Michael A. Weber, The Lancet Molecular PharmacologyHypertensionResistant HypertensionCardiovascular DiseaseAntihypertensive Therapy	2022	206
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction Sunil V. Rao, Bodo Kirsch, Deepak L. Bhatt, Circulation	2022	142
Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry Kanjana Perera, Thomas Vanassche, Jackie Bosch, International Journal of Stroke	2016	137
<i>Staphylococcus aureus</i> endocarditis: distinct mechanisms of bacterial adhesion to damaged and inflamed heart valves Laurens Liesenborghs, Severien Meyers, Marleen Lox, European Heart Journal	2019	137
Adhesion of Staphylococcus aureus to the vessel wall under flow is mediated by von Willebrand factor–binding protein Jorien Claes, Thomas Vanassche, Marijke Peetermans, Blood	2014	117

Page 1